Adherence

Intermittent empagliflozin administration (up to 14 days/month) improves dietary self-management and reduces energy intake in type 2 diabetes patients, achieving HbA1c and weight loss outcomes equivalent to daily administration.

For type 2 diabetes patients struggling with daily medication adherence or dietary control, an intermittent empagliflozin regimen (10mg, up to 14 days/month) may be a viable strategy. This approach allows patients to take the medication on days they perceive their diet was poor, potentially improving their overall dietary self-management and motivation. Clinical results (HbA1c and weight loss) were equivalent to daily dosing, suggesting that this flexible approach can maintain efficacy while reducing the burden of daily medication.